Protocol No.: RM-493-035

SETMELANOTIDE RM-493-035 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Principal Investigator
Barghouthi, Nadia
Phase
III
Age Group
Both
Applicable Disease Site
Weight Loss
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Jonathon Dukich, RN
Clinical Research Coordinator
Phone: +1 304-293-1436

View on ClinicalTrials.gov